Alternative therapies to address the unmet medical needs of patients with phenylketonuria

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 6, 2015, Pages 791-800

  Blau, Nenad ^a,b   Longo, Nicola ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Executive function; Phenylalanine ammonia lyase; Phenylketonuria; Sapropterin

Indexed keywords

BACTERIAL ENZYME; CINNAMIC ACID; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; PHENYLALANINE AMMONIA LYASE; RECOMBINANT ENZYME; RECOMBINANT PHENYLALANINE AMMONIA LYASE; SAPROPTERIN; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; BIOPTERIN; RECOMBINANT PROTEIN;

ALTERNATIVE MEDICINE; AMINO ACID METABOLISM; ANABAENA VARIABILIS; DIET RESTRICTION; DIETARY COMPLIANCE; DIZZINESS; ENCAPSULATION; ENZYME ACTIVITY; ENZYME REPLACEMENT; ERYTHROCYTE; EXECUTIVE FUNCTION; HUMAN; INJECTION SITE REACTION; NONHUMAN; PHENYLKETONURIA; REVIEW; ANALOGS AND DERIVATIVES; ENZYMOLOGY; PHENYLKETONURIAS;

ANABAENA VARIABILIS; BIOPTERIN; ENZYME REPLACEMENT THERAPY; HUMANS; PHENYLALANINE AMMONIA-LYASE; PHENYLKETONURIAS; RECOMBINANT PROTEINS;

EID: 84925854900     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1013030     Document Type: Review

References (33)

1. Scriver CR.The PAH gene, phenylketonuria, and a paradigm shift.Hum Mutat 2007; 28: 831-45
2. Blau N, van Spronsen FJ, Levy HL.Phenylketonuria.Lancet 2010; 376: 1417-27
3. Feillet F, van Spronsen FJ, MacDonald A, et al.Challenges and pitfalls in the management of phenylketonuria.Pediatrics 2010; 126: 333-41
4. van Spronsen FJ, de Groot MJ, Hoeksma M, et al.Large neutral amino acids in the treatment of PKU: from theory to practice.J Inherit Metab Dis 2010; 33: 671-6
5. Santos-Sierra S, Kirchmair J, Perna AM, et al.Novel pharmacological chaperones that correct phenylketonuria in mice.Hum Mol Genet 2012; 21: 1877-87
6. Blau N.Sapropterin dihydrochloride for phenylketonuria and tetrahydrobiopterin deficiency.Expert Rev Endocrinol Metabol 2010; 5: 483-94
7. Heintz C, Cotton RG, Blau N.Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria.Hum Mutat 2013; 34: 927-36
8. Blau N, Shen N, Carducci C.Molecular genetics and diagnosis of phenylketonuria: state of the art.Expert Rev Mol Diagn 2014; 14: 655-71
9. Wettstein S, Underhaug J, Perez B, et al.Linking genotypes database with locusspecific database and genotype-phenotype correlation in phenylketonuria.Eur J Hum Genet 2014; Epub ahead of print
10. Pey AL, Stricher F, Serrano L, et al.Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases.Am J Hum Genet 2007; 81: 1006-24
11. Staudigl M, Gersting SW, Danecka MK, et al.The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response.Hum Mol Genet 2011; 20: 2628-41
12. De Maria R, Campolo J, Frontali M, et al.Effects of sapropterin on endothelium-dependent vasodilation in patients with CADASIL: a randomized controlled trial.Stroke 2014; 45: 2959-66
13. Keil S, Anjema K, van Spronsen FJ, et al.Long-Term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study.Pediatrics 2013; 131: e1881-8
14. Shintaku H, Ohura T.Sapropterin is safe and effective in patients less than 4-years-old with BH-responsive phenylalanine hydroxylase deficiency.J Pediatr 2014; 165: 1241-4
15. Longo N, Siriwardena K, Feigenbaum A, et al.Long-Term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy.Genet Med 2014; Epub ahead of print
16. Hoskins JA, Jack G, Wade HE, et al.Enzymatic control of phenylalanine intake in phenylketonuria.Lancet 1980; 1: 392-4
17. Sarkissian CN, Gamez A, Wang L, et al.Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria.Proc Natl Acad Sci USA 2008; 105: 20894-9
18. Sarkissian CN, Kang TS, Gamez A, et al.Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.Mol Genet Metab 2011; 104: 249-54
19. Longo N, Harding CO, Burton BK, et al.Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 doseescalation trial.Lancet 2014; 384: 37-44
20. Yew NS, Dufour E, Przybylska M, et al.Erythrocytes encapsulated with phenylalanine hydroxylase exhibit improved pharmacokinetics and lowered plasma phenylalanine levels in normal mice.Mol Genet Metab 2013; 109: 339-44
21. Rossi L, Pierige F, Carducci C, et al.Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBRPah mice.J Control Release 2014; 194C: 37-44
22. Levy HL, Milanowski A, Chakrapani A, et al.Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.Lancet 2007; 370: 504-10
23. Burton BK, Grange DK, Milanowski A, et al.The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6Rtetrahydrobiopterin): a phase II, multicentre, open-label, screening study.J Inherit Metab Dis 2007; 30: 700-7
24. Wasserstein M, Burton B, Cederbaum S.Results of a Phase II, multicenter, openlabel study of sapropterin dihydrochloride in subjects with hyperphenylalaninemia related to primary BH4 deficiency.Presented at the Annual Meeting of the American Society for Human Genetics (ASHG), 2008; 11-15 November 2008; Philadelphia, PA, USA
25. Lee P, Treacy EP, Crombez E, et al.Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria.Am J Med Genet A 2008; 146A: 2851-9
26. Trefz FK, Burton BK, Longo N, et al.Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebocontrolled study.J Pediatr 2009; 154: 700-7
27. Burton BK, Nowacka M, Hennermann JB, et al.Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.Mol Genet Metab 2011; 103: 315-22
28. Fernhoff PM, Burton B, Nowacka M, et al.PKU 008: a long-Term, open-label study of sapropterin dihydrochloride (Kuvan) in PKU subjects.Presented at the American College of Medical Genetics Annual Meeting; 25-29 March 2009; FL USA
29. Douglas TD, Ramakrishnan U, Kable JA, et al.Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride.Health Qual Life Outcomes 2013; 11: 218
30. Grange DK, Hillman RE, Burton BK, et al.Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry.Mol Genet Metab 2014; 112: 9-16
31. Available from: www.Clinicaltrials.gov [Accessed 6 December 2014
32. BioMarin.Press Release 26 Sep 2012 Available from: http://investors.bmrn.com/releasedetail.cfm?ReleaseID=716661
33. BioMarin.Press Release 5 June 2013 Available from: http://investors.bmrn.com/releasedetail.cfm?ReleaseID=769256